Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
EVENTS PER QUARTER · HOVER FOR EMPLOYEE COUNTS
Vertex Pharmaceuticals Incorporated has announced that it will lay off 125 employees in Rhode Island as part of a consolidation of its offices. This decision reflects the company's ongoing efforts to streamline operations and reduce costs. The layoffs are part of a broader strategy to enhance efficiency within the organization. The affected employees will be notified as the company moves forward with its restructuring plans. Vertex's actions come amid a challenging economic environment, prompting the need for workforce adjustments.
Vertex Pharmaceuticals Incorporated has announced that it will lay off 125 employees in Rhode Island. This decision comes as part of the company's efforts to streamline operations and reduce costs. The layoffs are expected to take effect immediately, impacting a significant portion of the workforce at the Rhode Island facility. Vertex has not specified the departments affected by these layoffs, but the move reflects ongoing challenges within the pharmaceutical industry. The company aims to focus on its core projects while managing its resources more effectively.
Vertex Pharmaceuticals Incorporated has laid off 140 employees after deciding to discontinue its diabetes asset. This decision reflects a strategic shift within the company as it focuses on other areas of its business. The layoffs are part of a broader restructuring effort aimed at optimizing operations and reallocating resources. While specific details about the affected locations or departments were not disclosed, this move indicates the company's commitment to streamline its workforce in response to changing market conditions.
No one has shared a story from Vertex Pharmaceuticals Incorpor yet. Went through a layoff here? Your experience helps others feel less alone.
Share your story →We'll email you the moment a new layoff is reported here.